Format

Send to

Choose Destination
Nat Rev Cancer. 2005 Nov;5(11):857-66.

Mitochondrial tumour suppressors: a genetic and biochemical update.

Author information

1
Apoptosis and Tumour Physiology Laboratory, Cancer Research UK, the Beatson Institute for Cancer Research, Switchback Road, Glasgow G61 1BD, UK. e.gottlieb@beatson.gla.ac.uk

Abstract

Since the discovery 5 years ago that the D-subunit of succinate dehydrogenase (SDHD) can behave as a classic tumour suppressor, other nuclear-encoded mitochondrial proteins (SDHB, SDHC and fumarate hydratase) have been implicated in tumour susceptibility. Mutations in these proteins are principally involved in familial predisposition to benign tumours, but the spectrum of inherited lesions is increasingly recognized to include malignant tumours, such as malignant phaeochromocytomas and renal cell carcinomas. Here we review recent advances in the field of mitochondrial tumour suppressors, the biochemical pathway that links mitochondrial dysfunction with tumorigenesis, and potential therapeutic approaches to these malignancies.

PMID:
16327764
DOI:
10.1038/nrc1737
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center